AngioDynamics just watched a long running transformation story collide with a brutal trading day. The stock sank about 21% after the Q1 2027 release, even as the medical device group posted revenue of US$80.9m and kept full year guidance intact.
For a business still reporting a net loss of US$7.1m, the headline is simple. Med Tech products are growing into almost half of sales and lifting gross margin close to 60%. However, that progress was not enough to stop investors marking the shares sharply lower on the day.
Love the shift toward higher margin Med Tech at AngioDynamics but uneasy about a business that is still loss making after a 21% one day share price drop? Take a look at our 20 high quality undiscovered gems.
